Kura Oncology: Caspian Therapeutics plans Phase 1 study of diabetes drug candidate KO-7246

Kura Oncology announced that Caspian Therapeutics plans to launch a Phase 1 program for KO-7246, an oral menin inhibitor for metabolic disease, aimed at restoring beta-cell function and insulin production.